BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ashrafizadeh M, Zarrabi A, Hushmandi K, Zarrin V, Moghadam ER, Zabolian A, Tavakol S, Samarghandian S, Najafi M. PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs. Life Sciences 2020;256:117899. [DOI: 10.1016/j.lfs.2020.117899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Beserra DR, Alberca RW, Branco ACCC, Oliveira LM, de Souza Andrade MM, Gozzi-silva SC, Teixeira FME, Yendo TM, da Silva Duarte AJ, Sato MN, Xu B. Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity. Journal of Immunology Research 2022;2022:1-9. [DOI: 10.1155/2022/9764002] [Reference Citation Analysis]
2 Zhou Z, Liu Q, Zhang G, Mohammed D, Amadou S, Tan G, Zhang X. HOXA11-AS1 Promotes PD-L1-Mediated Immune Escape and Metastasis of Hypopharyngeal Carcinoma by Facilitating PTBP1 and FOSL1 Association. Cancers 2022;14:3694. [DOI: 10.3390/cancers14153694] [Reference Citation Analysis]
3 Vaxevanis CK, Friedrich M, Tretbar SU, Handke D, Wang Y, Blümke J, Dummer R, Massa C, Seliger B. Identification and characterization of novel CD274 (PD-L1) regulating microRNAs and their functional relevance in melanoma. Clin Transl Med 2022;12:e934. [PMID: 35802807 DOI: 10.1002/ctm2.934] [Reference Citation Analysis]
4 Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res 2022;41:214. [PMID: 35773731 DOI: 10.1186/s13046-022-02406-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, Sethi G, Zarrabi A, Kumar AP, Tan SC, Papadakis M, Alexiou A, Islam MA, Mostafavi E, Ashrafizadeh M. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol 2022;15:83. [PMID: 35765040 DOI: 10.1186/s13045-022-01305-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ashrafizadeh M, Zarrabi A, Karimi‐maleh H, Taheriazam A, Mirzaei S, Hashemi M, Hushmandi K, Makvandi P, Nazarzadeh Zare E, Sharifi E, Goel A, Wang L, Ren J, Nuri Ertas Y, Kumar AP, Wang Y, Rabiee N, Sethi G, Ma Z. (Nano)platforms in bladder cancer therapy: Challenges and opportunities. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ashrafizadeh M, Zarrabi A, Mostafavi E, Aref AR, Sethi G, Wang L, Tergaonkar V. Non-coding RNA-based regulation of inflammation. Semin Immunol 2022;:101606. [PMID: 35691882 DOI: 10.1016/j.smim.2022.101606] [Reference Citation Analysis]
8 Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022;:103680. [PMID: 35405273 DOI: 10.1016/j.critrevonc.2022.103680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
9 Ashrafizadeh M, Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Hashemi F, Hushmandi K, Hashemi M, Nabavi N, Crea F, Ren J, Klionsky DJ, Kumar AP, Wang Y. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res 2022;41:105. [PMID: 35317831 DOI: 10.1186/s13046-022-02293-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
10 Anaya-Ruiz M, Perez-Santos M. Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment. Pharm Pat Anal 2021. [PMID: 34875853 DOI: 10.4155/ppa-2021-0016] [Reference Citation Analysis]
11 Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M. Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. Onco Targets Ther 2021;14:5275-91. [PMID: 34848970 DOI: 10.2147/OTT.S283892] [Reference Citation Analysis]
12 Mirzaei S, Gholami MH, Ang HL, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Delfi M, Khan H, Ashrafizadeh M, Sethi G, Kumar AP. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells 2021;10:3348. [PMID: 34943856 DOI: 10.3390/cells10123348] [Reference Citation Analysis]
13 Yu Z, Liu Y, Li Y, Zhang J, Peng J, Gong J, Xia Y, Wang L. miRNA-338-3p inhibits glioma cell proliferation and progression by targeting MYT1L. Brain Res Bull 2021;179:1-12. [PMID: 34848272 DOI: 10.1016/j.brainresbull.2021.11.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Gu J, Liu Y, Qi T, Qian W, Hu D, Feng W. Long non-coding RNA DUXAP8 elevates RCN2 expression and facilitates cell malignant behaviors and angiogenesis in cervical cancer via sponging miR-1297. Diagn Pathol 2021;16:105. [PMID: 34774078 DOI: 10.1186/s13000-021-01145-9] [Reference Citation Analysis]
15 Najafi S, Tan SC, Raee P, Rahmati Y, Asemani Y, Lee EHC, Hushmandi K, Zarrabi A, Aref AR, Ashrafizadeh M, Kumar AP, Ertas YN, Ghani S, Aghamiri S. Gene regulation by antisense transcription: A focus on neurological and cancer diseases. Biomed Pharmacother 2021;145:112265. [PMID: 34749054 DOI: 10.1016/j.biopha.2021.112265] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
16 Mirzaei S, Saebfar H, Gholami MH, Hashemi F, Zarrabi A, Zabolian A, Entezari M, Hushmandi K, Samarghandian S, Aref AR, Ashrafizadeh M, Khan H. MicroRNAs regulating SOX2 in cancer progression and therapy response. Expert Rev Mol Med 2021;23:e13. [PMID: 34583803 DOI: 10.1017/erm.2021.15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Li H, Zheng C, Han J, Zhu J, Liu S, Jin T. PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective. Front Cell Neurosci 2021;15:716747. [PMID: 34381337 DOI: 10.3389/fncel.2021.716747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Mirzaei S, Gholami MH, Zabolian A, Saleki H, Farahani MV, Hamzehlou S, Far FB, Sharifzadeh SO, Samarghandian S, Khan H, Aref AR, Ashrafizadeh M, Zarrabi A, Sethi G. Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer. Pharmacol Res 2021;171:105759. [PMID: 34245864 DOI: 10.1016/j.phrs.2021.105759] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Bailly C, Thuru X, Quesnel B. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers (Basel) 2021;13:3034. [PMID: 34204509 DOI: 10.3390/cancers13123034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Chen L, Musa AE. Boosting immune system against cancer by resveratrol. Phytother Res 2021. [PMID: 34101276 DOI: 10.1002/ptr.7189] [Reference Citation Analysis]
21 Han X, Liu J, Liu Y, Mou L, Li C. LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p. Cancer Manag Res 2021;13:4393-401. [PMID: 34103994 DOI: 10.2147/CMAR.S305547] [Reference Citation Analysis]
22 Xu Y, Song G, Xie S, Jiang W, Chen X, Chu M, Hu X, Wang ZW. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther 2021;29:1958-69. [PMID: 33932597 DOI: 10.1016/j.ymthe.2021.04.029] [Reference Citation Analysis]
23 Delfi M, Sartorius R, Ashrafizadeh M, Sharifi E, Zhang Y, De Berardinis P, Zarrabi A, Varma RS, Tay FR, Smith BR, Makvandi P. Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. Nano Today 2021;38:101119. [PMID: 34267794 DOI: 10.1016/j.nantod.2021.101119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
24 You L, Wu W, Wang X, Fang L, Adam V, Nepovimova E, Wu Q, Kuca K. The role of hypoxia-inducible factor 1 in tumor immune evasion. Med Res Rev 2021;41:1622-43. [PMID: 33305856 DOI: 10.1002/med.21771] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
25 Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane Resistance. Cancers (Basel). 2020;12. [PMID: 33182737 DOI: 10.3390/cancers12113323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]